DEA Slaps Seven New Opioids into Ban List for Safety
Published Date: 6/26/2025
Proposed Rule
Summary
The DEA is temporarily putting seven new benzimidazole-opioids into Schedule I, meaning they’re now treated as highly controlled and illegal without special permission. This affects anyone who makes, sells, studies, or even holds these drugs, with strict rules and penalties kicking in right away. The move helps keep dangerous substances off the streets while the DEA finishes its full review.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Seven Benzimidazole-Opioids Placed in Schedule I
The DEA is temporarily placing seven benzimidazole-opioid substances into Schedule I of the Controlled Substances Act. When finalized, the Schedule I regulatory controls and the administrative, civil, and criminal sanctions that apply to Schedule I substances will apply to anyone who manufactures, distributes, reverse distributes, imports, exports, conducts research or instructional activities or chemical analysis, or possesses these seven substances.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12144 — Importer of Controlled Substances Application: Wedgewood Pharmacy LLC
Wedgewood Pharmacy LLC wants to become an official importer of certain strong controlled substances, like Etorphine HCL and Thiafentanil. This affects drug manufacturers and others in the supply chain who can comment or request a hearing by July 17, 2026. No direct costs are mentioned, but the decision could impact how these drugs enter the U.S. market.
2026-12140 — Importer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
Previous / Next Documents
Previous: 2025-11711 — Magnuson-Stevens Act Provisions; Fisheries of the Northeastern United States; Fisheries of the Northeastern United States; 2025-2027 Atlantic Herring Fishery Specifications
Starting in 2025, new fishing limits for Atlantic herring and river herring will help protect fish populations and support rebuilding efforts through 2027. These changes affect fishermen in the Northeastern U.S. and aim to keep fishing sustainable while meeting updated science goals. The plan updates when the herring stock should be fully rebuilt, ensuring a healthy fishery for the future.
Next: 2025-11737 — Fisheries off West Coast States; Coastal Pelagic Species Fisheries; Annual Specifications; 2025-2026 Annual Specifications and Management Measures for Pacific Sardine
Starting July 1, 2025, most commercial fishing for Pacific sardines off Washington, Oregon, and California will be paused to help the sardine population bounce back. Fishermen can still catch sardines for live bait, small special fisheries, or as bycatch, but strict limits will keep the total catch low. This plan aims to protect the sardines while balancing fishing needs through June 30, 2026.